From today and for the next four weeks, lateral flow tests will be offered to all people attending a case at Manchester CJC who are not showing any symptoms of coronavirus (COVID-19). The test will also be offered to all staff, judiciary, contractors and legal professionals who visit the site. It will not be a public testing facility.

The tests are voluntary and will be carried out through lateral flow devices, which detect the presence or absence of coronavirus by applying a swab or saliva sample to the device’s absorbent pad. The sample runs along the surface of the pad, showing at the end a visual positive or negative result dependent on the presence of the virus.

The pilot will support the Department of Health and Social Care’s (DHSC) national testing programme by providing information on how rapid testing works in different public sector settings. HMCTS will use findings to decide how rapid testing could be rolled out nationally to other courts and tribunals across the country.

Kevin Sadler, Acting CEO of HMCTS, said:

We are pleased to be supporting DHSC in their national testing programme by running this pilot trial for lateral flow testing. The results will help develop and improve the national testing programme and inform how we could roll out rapid testing nationally to other courts and tribunals.

We’ve ensured that all our courts and tribunal buildings are safe and secure against COVID-19. This additional measure will provide further reassurance to those visiting our buildings.

All Manchester CJC court users will be given the opportunity to book a test slot. Users will be asked to register their details, and the test carried out using a lateral flow device testing kit. Specially trained staff who manage the testing site will supervise the test and process the results.

Once the test has been taken, NHS Test & Trace will send results by text or email in 30 minutes. If the test comes out negative, this indicates that the person is not infectious and the person will be permitted to remain in the building. If the test gives a positive result, the court user will be required to leave the court, return home quickly and directly, and follow NHS advice.

HMCTS continues to work with DHSC to explore regular nation-wide testing for staff, judiciary and professionals. There are practical issues to resolve before any wider roll out – not least space, staffing and supply of equipment. We will provide updates as soon as our plans evolve.

Every building we operate – including our Nightingale courts – meet the government’s Covid-secure guidelines, and public health experts have confirmed our arrangements remain sufficient to deal with the new strain of the virus.

Homeless prison leavers will be temporarily housed in basic hostels to reduce the risk of them reoffending, backed by £70 million of new investment.

With offenders around 50 per cent more likely to break the law again if released without somewhere to stay, this is the latest part of the Government’s work to tackle the root causes of crime. It follows last week’s £148 million investment to combat illegal drug supply and treat addictions, taking the total funding to £220 million.

More than £20 million will be invested in supporting prison leavers at risk of homelessness into temporary basic accommodation for up to 12 weeks, giving them the foundation for a crime-free life. Launching in five of the 12 National Probation Service regions, it will support around 3,000 offenders in its first year. While there, offenders will get help to find a permanent home so there is less reason for them to turn back to crime.

Getting prison leavers into stable accommodation provides the platform they need to find work and access treatment for addictions and mental health problems which are also proven to help reduce the risk of reoffending. Tackling all three together in this way could prevent thousands of people becoming victims each year and save some of the £18 billion annual cost of repeat crimes.

At least £23 million of funding will go towards the Government’s plans to build 200 new spaces in Approved Premises (APs), formerly known as bail hostels, which allow probation staff to closely monitor and support the highest-risk offenders in the community. It will also fund new training for staff, increased security, and vital repairs and maintenance. The expansion will see an extra 1,700 prison leavers receive closer supervision each year, boosting public safety.

Prisons and Probation Minister Lucy Frazer QC MP said:

Releasing prisoners without addressing why they ended up there in the first place, only leads them to reoffend and cause more harm.

By tackling homelessness, we are cutting crime, reducing drug and alcohol misuse and making our streets safer. This low-cost solution has the potential to save billions for the taxpayer and prevent thousands of people becoming victims.

Last week, the Government announced the largest increase in drug treatment funding in fifteen years as part of a £148 million investment to cut crime and protect people from the scourge of illegal drugs. It includes:

• An extra £80 million invested across England to increase the number of substance misuse treatment places for prison leavers and those diverted into tough and effective community sentences.
• £40 million of new money to tackle drugs supply – doubling the funding available for law enforcement to take down county lines gangs and drug kingpins.
• £28 million invested into piloting Project ADDER – a new intensive approach to tackling drug misuse, which combines targeted and tougher policing with enhanced treatment and recovery services. It will begin in five areas with some of the highest rates of drug misuse: Blackpool, Hastings, Middlesbrough, Norwich and Swansea Bay.

A further £6 million will be spent in the coming year improving the work done across Government to reduce reoffending. Dedicated staff will be appointed in an initial eleven prisons to act as brokers for prisoners so that they can get quicker access to accommodation, healthcare and employment support services as they are released.

The £20 million Prison Leavers Project is also underway bringing together charities, public and private partners to find and test new ways to prepare offenders for life on the outside and ensure they don’t fall back into criminal lifestyles. Local organisations will be able to bid for grants to join-up their existing services and a £1 million competition is being launched to encourage start-ups to create new technology-based support services.

Taken together, this £220 million investment represents a gear shift in the Government’s approach to tackling crime, helping to build back safer from the pandemic.

The commitment was made following the Chinese government’s imposition of the National Security Law in Hong Kong last year, in breach of its commitments under international law.

The visa reflects the UK’s historic and moral commitment to the people of Hong Kong who have had their rights and freedoms restricted.

Those with BN(O) status and their eligible family members will be able to come to the UK to live, study and work. As with other visas, after five years in the UK, they will be able to apply for settlement, followed by British citizenship after a further 12 months.

Prime Minister Boris Johnson said:

I am immensely proud that we have brought in this new route for Hong Kong BN(O)s to live, work and make their home in our country.

In doing so we have honoured our profound ties of history and friendship with the people of Hong Kong, and we have stood up for freedom and autonomy – values both the UK and Hong Kong hold dear.

Home Secretary Priti Patel said: 

Global Britain will always stand up for what is right and uphold our commitments. This new visa delivers on our promise to the people of Hong Kong, honouring our strong historic relationship and upholding their freedoms.

I look forward to welcoming people wanting to put down roots and build a new life with their family in the UK.

Foreign Secretary Dominic Raab said:

We have been clear we won’t look the other way when it comes to Hong Kong. We will live up to our historic responsibility to its people.

China’s imposition of the National Security Law in Hong Kong constitutes a clear and serious breach of the Sino-British Joint Declaration contrary to international law.

With the launch of this new visa route, BN(O) citizens will now have a choice to come and live, work and study in the UK.

Applicants for the visa with certain biometric passports will also be able to apply from home using a smartphone app to scan their passport rather than having to visit a visa application centre.

From 23 February, BN(O) status holders and their eligible family members who hold a biometric BN(O), Hong Kong Special Administrative Region or European Economic Area (EEA) passport can scan their passport on the app and complete their application from home. They will be the first non-EEA citizens to be able to do so.

The UK committed to this visa following the imposition of the National Security Law imposed by the Chinese government in June 2020, in a clear breach of the Sino-British Joint Declaration. The 1984 declaration is a legally binding treaty which commits to ensure the rights and freedoms of the people of Hong Kong and maintain Hong Kong’s high degree of autonomy.

From 15 July 2020 to 13 January 2021, approximately 7,000 BN(O) status holders and their dependants have been granted Leave Outside the Rules at the border. BN(O) status holders will not need to apply for the new route straight away. We have made the decision to extend the Leave Outside the Rules at the border scheme until after the route becomes fully digital.

In addition to the Immigration Health Surcharge, the visa fee payable to stay for five years will be £250 per person or applicants will also be able to apply to stay for 30 months which will cost £180 per person. This is lower than many other visas.

The UK government is working with civil society groups and others to welcome BN(O) status holders to all parts of the UK and help them integrate.

The study was conducted during the period the new COVID-19 variant was first observed in Kent and began to circulate widely, with today’s results showing it was effective against the variant during the phase 3 trial.

Thanks to the work of the government’s Vaccines Taskforce, the UK has secured 60 million doses of Novavax’s vaccine to be delivered in the second half of this year, if approved for use by the Medicines and Healthcare products Regulatory Agency (MHRA), who will assess whether the vaccine meets robust standards of safety, effectiveness and quality.

Last August Novavax announced plans to manufacture the bulk of the vaccine using FUJIFILM Diosynth Biotechnologies’s facilities in Billingham, Stockton-on-Tees. This will ensure that, once available, the vaccine can be supplied to the British public as soon as possible.

Business Secretary Kwasi Kwarteng said:

The results from the UK trial of Novavax’s vaccine look extremely promising, and I welcome the news that the company is planning to submit its data to the regulators.

The UK moved quickly to procure 60 million doses from Novavax and I’m pleased to confirm the bulk of the vaccine will be manufactured on Teesside and delivered during this year, if approved for use.

From the scientists and researchers to the thousands of UK trial volunteers, I am enormously grateful to everyone who is playing their part in this truly national effort to defeat this virus once and for all.

Health Secretary Matt Hancock said

This is positive news and, if approved by the medicines regulator, the Novavax vaccine will be a significant boost to our vaccination programme and another weapon in our arsenal to beat this awful virus.

I’m proud the UK is at the forefront of another medical breakthrough and I want to thank the brilliant scientists and researchers, as well as the tens of thousands of selfless volunteers who took park in clinical trials.

The NHS stands ready to roll this vaccine out as quickly as possible to those most at risk if it is authorised.

Vaccines Minister Nadhim Zahawi said:

Having taken part in Novavax’s vaccine trial myself, I am particularly thrilled to see such positive results. I want to thank the thousands of trial volunteers, without whom these results would not have been possible.

It will now be for the regulator to do its crucial work in assessing the efficacy and safety of this vaccine, but if approved it will be a further boost to our vaccination programme.

Novavax’s candidate differs from those currently being used in the UK, combining an engineered protein from the virus that causes COVID-19 with a plant-based ingredient to help generate a stronger immune response. Having a diverse portfolio of vaccines increases the chances of ensuring there is a vaccine available for everyone across the UK.

The data published today come from more than 15,000 people who were recruited through the National Institute of Health Research vaccine registry, which was launched in July 2020 to support the UK’s efforts to deliver vaccines for COVID-19. Nearly 4,000 people in the study were over the age of 65.

Through the Vaccines Taskforce, the UK has secured early access to 367 million doses of 7 of the most promising vaccines so far. To date, the UK government has invested over £230 million into manufacturing a successful vaccine.

The UK was the first country in the world to procure, authorise and then deploy both the Oxford/AstraZeneca and Pfizer/BioNTech vaccines.

Production of the Oxford University/AstraZeneca vaccine started last autumn where the bulk of the vaccine for the UK is being made in Oxfordshire and Staffordshire, with filling into vials taking place in North Wales.

In total, more than 7.4 million people across the UK have now had a least one dose of the vaccine.

Notes to editors

• The government’s vaccine supply and scheduled deliveries will fully support our target of offering a first vaccine dose to every person in the top four priority groups by mid-February.
• the members of the Joint Committee on Vaccination and Immunisation (JCVI) are independent experts who advise the UK on prioritisation at a population level for all vaccination and immunisation programmes; they have developed the prioritisation list of patient groups that is guiding the NHS vaccination programme and the committee keeps its advice under review and updates it as appropriate
• the government has a set process for approving any vaccine, with regulatory oversight provided by the MHRA
• this involves MHRA approving a product licence after the applicant has generated appropriate data to demonstrate the quality, safety and efficacy of the vaccine
• in total, the government has procured 60 million doses of the Novavax candidate, the bulk of which will be manufactured in the UK if the vaccine is approved by regulators
• through the government’s Vaccine Taskforce, the UK has secured early access to 367 million doses of 7 of the most promising vaccine candidates, including:
  • BioNTech/Pfizer – Approved – 40 million doses secured
  • Oxford/Astra Zeneca –Approved – 100 million doses secured
  • Moderna – Approved – 17 million doses secured
  • Novavax – Phase III – 60 million doses secured
  • Janssen – Phase III – 30 million doses secured
  • GSK/Sanofi – Phase I / II – 60 million doses secured
  • Valneva – Phase I / II – 60 million doses secured, with an option to acquire a further 130 million if the vaccine is proven to be safe, effective and suitable.
• the UK government has invested £127 million to fund a state-of-the-art manufacturing innovation centre in Braintree, Essex, in collaboration with the Cell and Gene Therapy Catapult, to accelerate the mass production of a successful Covid-19 vaccine in the UK
• due to open in December 2021, the centre will have the capacity to produce millions of doses of vaccines each month, ensuring the UK has the capabilities to manufacture both vaccines and advanced medicines, including for emerging diseases, far into the future The Government has also provided £4.7 million funding to the Catapult to ensure that the UK has the best skills and expertise in vaccine manufacturing and advanced therapies.
• the government has established a Rapid Deployment Facility with £8.75 million of investment which is manufacturing vaccines at scale.
• the government has also created the UK’s first dedicated Vaccine Manufacturing and Innovation Centre (VMIC) and accelerated its development with £93 million of investment
• this investment will rapidly accelerate the construction of the facility, enabling us to bring it online sooner. It will also have expanded capability for advanced vaccine process development, fill and finish and bulk manufacture
• in addition, the facility’s capacity will be significantly increased to be able to respond to this pandemic
• once open, it will be able to manufacture 70 million vaccines doses in just 6 months – enough for the UK population
• located in Oxfordshire, the centre will be the UK’s first not-for-profit organisation established to develop and advance the mass production of vaccines. This will boost the UK’s long-term capacity against future viruses